Retatrutide, by Soma Corp., is gaining increasing attention as a innovative treatment for metabolic regulation. This unique drug combines the activity of a GLP-1 receptor agonist and a GIP receptor agonist , designed to effectively promote reduced body fat but also address related metabolic facto